Table 1.
Patient’s laboratory results
| Examination | Patient’s level | Reference range |
|---|---|---|
| Blood tests | ||
| Total protein (g/dL) | 6.4 | 6.4–8.2 |
| Albumin (g/dL) | 3.0 | 3.9–5.1 |
| Sodium (mEq/L) | 153 | 138–145 |
| Potassium (mEq/L) | 2.9 | 3.6–4.8 |
| Chloride (mEq/L) | 109 | 100–110 |
| Calcium (mg/dL) | 20.4 | 8.6–10.1 |
| Adjusted calcium (mg/dL) | 21.4 | 8.6–10.1 |
| Phosphate (mg/dL) | 1.6 | 2.7–4.6 |
| Magnesium (mg/dL) | 1.5 | 1.8–2.4 |
| Blood urea nitrogen (mg/dL) | 83 | 8–20 |
| Creatinine (mg/dL) | 1.06 | 0.65–1.07 |
| eGFR (mL/min/1.73 m2) | 42.8 | ≥ 60 |
| Blood glucose (mg/dL) | 580 | 70–100 |
| HbA1c (%) | 13.9 | 4.6–6.2 |
| Alkaline phosphatase (IU/L) | 192 | 38–113 |
| IgG (mg/dL) | 951 | 870–1700 |
| IgA (mg/dL) | 290 | 110–410 |
| IgM (mg/dL) | 99 | 33–190 |
| Immunofixation Electrophoresis | - | - |
| Free light chains kappa/lambda ratio | 1.14 | 0.26–1.65 |
| PTH-INTACT (pg/mL) | 20 | 10–65 |
| PTHrP (pmoL/L) | < 1.0 | 0–1.0 |
| Anti-thyroid peroxidase antibody (IU/mL) | ≤ 3.0 | ≤ 3.0 |
| Anti-thyroglobulin antibody (IU/mL) | ≤ 5.0 | ≤ 5.0 |
| Thyrotrophin receptor antibody (IU/L) | 0.9 | < 2.0 |
| 1,25 dihydroxy vitamin D3 (pg/mL) | 14 | 20–60 |
| 25 hydroxy vitamin D (ng/mL) | 8.6 | ≥ 30.0 |
| Adrenocorticotropic Hormone (pg/mL) | 53.5 | 7.2–63.3 |
| Cortisol (µg/dL) | 25.3 | 4.4–21.1 |
| HTLV-1 antibody | - | - |
| Soluble interleukin-2 receptor (U/mL) | 1883 | 157–474 |
Abbreviations: eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; PTH, Parathyroid hormone; PTHrP, parathyroid hormone-related peptide; HTLV-1, Human T-cell Leukemia Virus type I
Note: eGFR was calculated using a modified version of the Modification of Diet in Renal Disease formula of the Japanese Society of Nephrology: eGFR (mL/min/1.73 m2) = 194 × −0.287 × serum creatinine− 1.094 (× 0.739 for women). Adjusted calcium = calcium + [4 − albumin])